Breast cancer markers

Cancer Letters

Volumn 243, Issue 2, 2006, Pages 145-159

  Giancotti, Vincenzo ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Breast cancer; Kinases; Markers

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; GEFITINIB; IMATINIB; LAPATINIB; LETROZOLE; PERTUZUMAB; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; TRASTUZUMAB;

BREAST CARCINOMA; CARCINOGENESIS; CELL CYCLE; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; ENZYME ACTIVATION; GENE LOCATION; GENETIC LINKAGE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 33749266896     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.01.035     Document Type: Review

References (103)

1. Goss P.E. The rise and current status of aromatase inhibitors in breast cancer treatment, in abstracts of san antonio breast cancer symposium. Breast Cancer Res. Treat. 88 (2004) S1
2. Surowiak P., Paluchowski P., Wysocka T., Wojnar A., and Zabel M. Steroid receptor status, proliferation and metallothionin expression in primary invasive ductal breast cancer. Pathol. Oncol. Res. 10 (2004) 207-211
3. Simpson P.T., Reis-Fiho J.S., Gale T., and Lakhani S. Molecular evolution of breast cancer. J. Pathol. 205 (2005) 248-254
4. Bocchinfuso W.P., and Korach K.S. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J. Mammary Gland Biol. Neoplasia 2 (1997) 323-334
5. Belguise K., Kersual N., Galtier F., and Chalbos D. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24 (2005) 1434-1444
6. Chu I., Blackwell K., Chen S., and Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 65 (2005) 18-25
7. Jones K.L., and Buzdar A.U. A review of adjuvant hormonal therapy in breast cancer. Endocr. Relat. Cancer 11 (2004) 391-406
8. Freedman O.C., Verma S., and Clemons M.J. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution ?. Cancer Treat. Rev. 31 (2005) 1-17
9. Frasor J., Danes J.M., Komm B., Chang K.C.N., Lyttle R., and Katzenellenbogen B.S. Profiling of estrogen up-and down-regulated gene expression in human breast cancers cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 (2003) 4562-4574
10. Ring A., and Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11 (2004) 643-658
11. Serrero G., Dai H., Yue B., Tian C., and Tangkeangsirisin W. Neutralization of the autocrine growth factor PCDGF/GP88 by treatment with anti-PCDGF/GP88 monoclonal antibody restores tamoxifen responsiveness in tamoxifen resistant human breast cancer cells, in abstracts of san antonio breast cancer symposium. Breast Cancer Res. Treat. 88 (2004) S33
12. Massarweh S., Osborne C.K., Wakeling A.E., and Shiff R. Tamoxifen resistence in a breast cancer xenograft model coincides with a switch from a ER+/PgR+ to an ER+/PgR-phenotype accompanied by EGFR/HER2 activation, in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 88 (2004) S18
13. Arpino G., Weiss H., Lee A., Schiff R., Osborne C.K., and Elledge R.M. Estrogen receptor positive (ER+), progesterone receptor negative (PgR-) breast cancer: new insights into molecular mechanisms and clinical application, in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 88 (2004) S21
14. Turner J., Bentey R., Tao Y., Singh B., Evans D.B., Krause A., et al. Changes in tumor grade with neoadjuvant endocrine therapy: morphology evidence for fundamental differences in the anti-tumor effects of letrozole and tamoxifen, in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 88 (2004) S37
15. Schiff R., and Osborne C.K. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res. 7 (2005) 205-211
16. DiGiovanna M.P., Stern D.F., Edgerton S.M., Whalen S.G., Dan Moore II, and Thor A.D. Relationship of epidermal growth factor receptor expression to ErbB-2 signalling activity and prognosis in breast cancer patients. J. Clin. Oncol. 23 (2005) 1152-1160
17. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signalling network: receptor heterodimerization in development and cancer. Eur Mol. Biol. Org. J. 19 (2000) 3159-3167
18. Stern D.F. Tyrosine kinase signaling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 176 (2000) 176-183
19. Romieu-Mourez R., Landesman-Bollag E., Seldin D.C., and Sonenshein G.E. Protein kinase CK2 promotes aberrant activation of nuclear factor-κB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 62 (2002) 6770-6778
20. Arsura M., and Cavin L.G. Nuclear factor-κB and liver carcinogenesis. Cancer Lett. 229 (2005) 157-169
21. Arpino G., Weiss H., Wakeling A.E., Osborne K., and Schiff R. Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition, in abstracts of san antonio breast cancer symposium. Breast Cancer Res. Treat. 88 (2004) S15
22. Arteaga C.L., O'Neil A., Moulder S.L., Pins M., Sparano J.A., Sledge G.W., et al. ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzumab and gefitinib ('Iressa') in patients (pts) with HER-2 overexpressing metastatic breast cancer (met br ca), in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 88 (2004) S15
23. Munstermann U., Fritz G., Seitz G., Lu Y.P., Schneider H.R., and Issinger O.G. Casein kinase II elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur J. Biochem. 189 (1990) 251-257
24. Landesman-Bollag E., Romieu-Mourez R., Song D.H., Sonenshein G.E., Cardiff R.D., and Seldin D.C. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20 (2001) 3247-3257
25. Romieu-Mourez R., Landesman-Bollag E., Seldin D.C., Traish A.M., Mercurio F., and Sonenshein G.E. Roles of IKK kinases and protein kinase CK2 in activation of nuclear-factor κB in breast cancer. Cancer Res. 61 (2001) 3810-3818
26. Cha T.-L., Qiu L., Chen C.-T., Wen Y., and Hung M.-C. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res. 65 (2005) 2287-2295
27. Zhang L., Lau Y.-K., Xia W., Hortobagyi G.N., and Hung M.-C. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory of paclitaxel. Clin. Cancer Res. 5 (1999) 343-353
28. Zhang L., Chang C.-J., Bacus S.S., and Hung M.-C. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res. 55 (1995) 3890-3896
29. Yang W., Shen J., Wu M., Arsura M., Fitzgerald M., Suldan Z., et al. Repression of transcription of p27 (Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 20 (2001) 1688-1702
30. Spector N.L., Xia W., Burris III H., Hurwitz H., Dees E.C., Dowlati A., et al. Study of the biological effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 23 (2005) 1-11
31. Lo H.-W., Xia W., Wei Y., Ali-Seyed M., Huang S.-F., and Hung M.-C. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 65 (2005) 338-348
32. Sgarra R., Rustighi A., Tessari M.A., Di Bernardo J., Altamura S., Fusco A., et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. Fed. Eur. Biochem. Soc. Lett. 574 (2004) 1-8
33. Sgarra R., Tessari M.A., Di Bernardo J., Rustighi A., Zago P., Liberatori S., et al. Discovering high mobility group A molecular partners in tumour cells. Proteomics 5 (2005) 1494-1506
34. Diana F., Di Bernardo J., Sgarra R., Tessari M.A., Rustighi A., Fusco A., et al. Differential HMGA expression and post-translational modifications in prostatic tumor cells. Int. J. Oncol. 26 (2005) 515-520
35. Tessari M.A., Gostissa M., Altamura S., Sgarra R., Rustighi A., Salvagno C., et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol. Cell. Biol. 23 (2003) 9104-9116
36. Song G., Ouyang G., and Bao S. The activation of Akt/PKB signalling pathway and cell survival. J. Cell. Mol. Med. 9 (2005) 59-71
37. Nicholson K.M., and Anderson NG N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 14 (2002) 381-395
38. Nicholson K.M., Streuli C.H., and Anderson N.G. Autocrine signalling through erbB receptors promoters constitutive activation of protein kinase B/Akt in breast cancer cell lines. Breast Cancer Res. Treat. 81 (2003) 117-128
39. Al-Khouri A.M., Ma Y., Togo S.H., Williams S., and Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinase and glycogen synthase kinase 3beta. J. Biol. Chem. 280 (2005) 35195-35202
40. Farago M., Dominguez I., Landsmann-Bollag E., Xu X., Rosner A., Cardiff R.D., et al. Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res. 65 (2005) 5792-5801
41. Le X.F., Pruefer F., and Bast R.C. HER-2 targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathway. Cell Cycle 4 (2005) 87-95
42. Sen P., Mukherjee S., Ray D., and Raha S. Involvement of the Akt/PKB signalling pathway with disease processes. Mol. Cell. Biochem. 253 (2003) 241-246
43. Kops G.J.P.L., and Burgering B.M.T. Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT). J. Anat. 197 (2000) 571-574
44. West K.A., Sianna Castillo S., and Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 5 (2002) 234-248
45. Nicholson R.I., Giles M.G., Hutcheson I.R., Madden T., and Gee J.M.W. Impact of altered growth factor signalling on endocrine response in breast cancer and the transition from ER+ to ER- disease. Breast Cancer Online 7 (2004) 1-5
46. Yee D., and Sachdev D. Targeting the insulin-like growth factor receptor pathway in breast cancer, in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 88 (2004) S4
47. Dowsett M., Nicholson R.I., and Pietras R.J. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistence. Breast Cancer Res. Treat. 93 Suppl. 4 (2005) 11-18
48. Lacroix M., and Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83 (2004) 249-289
49. Gee J.M., Robetson J.F., Ellis I.O., and Nicholson R.I. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer 95 (2001) 247-254
50. Kahlert S., Nuedling S., van Eickels M., Vetter H., Meyer R., and Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathaway. J. Biol Chem. 275 (2000) 18447-18453
51. Dumont J.A., Bitonti A.J., Wallace C.D., Baumann R.J., Cashman E.A., and Cross-Doersen D.E. Progression of MCF-7 breast cancer cells to anti-estrogen resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ. 7 (1996) 351-359
52. Schiff R., Reddy P., Ahotupa M., Coronado-Heinsohn E., Grim M., and Hilsenbeck S.G. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumour in vivo. J. Natl Cancer Inst. 29 (2000) 1926-1934
53. Chen D., Washbrook E., Sarwar N., Bates G.J., Pace P.E., Thirunuvakkarasu V., et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation specific antisera. Oncogene 21 (2002) 4921-4931
54. Kim D.W., Sovak M.A., Zanieski G., Nonet G., Romieu-Mourez R., Lau A.W., et al. Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary glands. Carcinogenesis 21 (2000) 871-879
55. Cogswell P.C., Guttridge D.C., Funkhouser W.K., and Baldwin A.S. Selective activation of NF-kappaB subunits in human breast cancer: potential roles for NF-kappa B2/p52 and Bcl-3. Oncogene 19 (2000) 1123-1131
56. Pianetti S., Arsura M., Romieu-Mourez R., Coffey R.J., and Sonenshein G.E. Her-2 overexpression induces NF-kappaB via a PI3-kinase/Akt Pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20 (2001) 1287-1299
57. Chiappetta G., Tallini G., De Blasio M.C., Pentimalli F., de Nigris F., Losito S., et al. FRA-1 expression in hyperplastic and neoplastic thyroid diseases. Clin. Cancer Res. 6 (2000) 4300-4306
58. Battista S., de Nigris F., Fedele M., Chiappetta G., Scala S., Vallone D., et al. Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene 17 (1998) 377-385
59. Vallone D., Battista S., Pierantoni G.M., Fedele M., Casalino L., Santoro M., et al. Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. Eur Mol. Biol. Org. J. 16 (1997) 5310-5321
60. Yang Z., Zhang H., and Kumar R. Regulation of E-cadherin. Breast Cancer Online 8 (2005) 1-4
61. Miyazawa J., Mitoro A., Kawashiri S., Chada K.K., and Imai K. Expression of mesenchyme-specofic gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 64 (2004) 2024-2029
62. Sarriò D., Moreno-Bueno G., Hardisson D., Sánchez-Estévez C., Guo M., Herman J.G., et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int. J. Cancer 106 (2003) 208-215
63. Hajra K.M., Chen D., and Fearon E.R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62 (2002) 1613-1618
64. Abd El-Rehim D.M., Ball G., Pinder S.E., Rakha E., Paish E., Robertson J.F.R., et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int. J. Cancer 116 (2005) 340-350
65. Rakha E.A., Armour J.A.L., Pinder S.E., Paish C.E., and Ellis I.O. High-resolution analysis of 16q22.1 in breast carcinoma using amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry. Int. J. Cancer 114 (2005) 720-729
66. Starita L.M., and Parvin J.D. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr. Opin. Cell. Biol. 15 (2003) 345-350
67. Butcher D.T., Mancini-DiNardo D.N., Archer T.K., Rodenhiser D.I., and binding D.N.A. sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter. Int. J. Cancer 111 (2004) 669-678
68. Calderon-Margalit R., and Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of literature. Int. J. Cancer 112 (2004) 357-364
69. Baldassarre G., Battista S., Belletti B., Thakur S., Pentimalli F., Trapasso F., et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol. Cell. Biol. 23 (2003) 2225-2238
70. Chiappetta G., Botti G., Monaco M., Pasquinelli R., Pentimalli F., Di Bonito M., et al. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin. Cancer Res. 10 (2004) 7637-7644
71. Hwang E.S., McLennan J., Crawford B.B., Esserman L.J., and Ziegler J.L. Incidence and prevalence of ductal carcinoma in situ in BRCA mutation carriers, in abstracts of San Antonio Breast Cancer Symposium. Breast Cancer Res. Treat. 88 (2004) S11
72. Varadhachary A., Wolf J.S., Petrak K., O'Malley B.W., Spadaro M., Curcio C., et al. Oral lactoferrin nhibits growth of established tumors and potentiates conventional chemotherapy. Int. J. Cancer 111 (2004) 398-403
73. Benaïssa M., Peyrat J.-P., Hornez L., Mariller C., Mazurier J., and Pierce A. Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int. J. Cancer 114 (2005) 299-306
74. Teng C.T., Gladwell W., Raphiou I., and Liu E. Methylation and expression of the lactoferrin gene in human tissues and cancer cells. Biometals 17 (2004) 317-323
75. Miyamoto K., Fukutomi T., Akashi-Tanaka S., Hasegawa T., Asahara T., Sugimura T., et al. Identification of 20 genes aberrantly methylated in human breast cancer. Int. J. Cancer 116 (2005) 407-414
76. Stokes K., Alston-Mills B., and Teng C. Estrogen response element and the promoter context of the human and mouse lactoferrin genes influence estrogen receptor α-mediated transactivation activity in mammary gland cells. J. Mol. Endocrinol. 33 (2004) 315-334
77. Park S.-E., Xu J., Frolova A., Liao L., O'Malley B.W., and Katzenellenbogen B.S. Genetic deletion of the repressor of estrogen receptor activity (REA) enhances the response to estrogen in target tissues in vivo. Mol. Cell. Biol. 25 (2005) 1989-1999
78. Santos-Rosa H., and Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J. Cancer 41 (2005) 2381-2402
79. Connor E.E., Wood D.L., Sonstegard T.S., da Mota A.F., Bennett G.L., Williams J.L., et al. Chromosomal mapping and quantitative analysis of estrogen-related receptor alpha-1, estrogen receptors alpha and beta and progesterone receptor in the bovine mammary gland. J. Endocrinol. 185 (2005) 593-603
80. Boumendjel A., Baubichon-Cortay H., Trompier D., Perrotton T., and Di Pietro A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med. Res. Rev. 25 (2005) 453-472
81. Tian Q., Zhang J., Chan E., Duan W., and Zhou S. Multidrug resistance proteins (MPRs) and implication in drug development. Drug. Dev. Res. 64 (2005) 1-18
82. Özvegy-Laczka C., Cserepes J., Elkind N.B., and Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist. Updat. 8 (2005) 15-26
83. Filipitis M., Pohl G., Rudas M., Dietze O., Lax S., Grill R., et al. Clinical role of multidrug resistence protein 1 expression in chemotherapy resistence in early-stage breast cancer: the austrian breast and colorectal cancer study group. J. Clin. Oncol. 23 (2005) 1161-1168
84. Mao Q., and Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps. J. 7 (2005) E118-E133
85. Kage K., Fujita T., and Sugimoto Y. Role of Cys-603 in the dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci. 96 (2005) 866-872
86. Merino G., Jonker J.W., Wagenaar E., van Herwaarden A.E., and Schinkel A.H. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetis, hepatobiliary excretion, and milk secretion of theantibiotic nitrofurantoin. Mol. Pharmacol. 67 (2005) 1758-1764
87. Albermann N., Schmitz-Winnenthal F.H., Z'graggen K., Volk C., Hoffmann M.M., Haefeli W.E., et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in perpheral blood mononuclear cells and their raletionship with the expression in untestine and liver. Biochem. Pharmacol. 70 (2005) 949-958
88. Minisini A.M., Di Loreto C., Mansutti M., Artico D., Pizzolitto S., Piga A., et al. Topoisomerase Iiα and APE/ref-1 are associated with pathologic response to primary anthracycline-base chemotherapy for breast cancer. Cancer Lett. 224 (2005) 133-139
89. Cui M.Y., Zhang M., Testell R., Curran E.M., Welshons W.V., and Fuqua S.A.W. Phosphorylation of estrogen receptor α bloks its acetylation and regulates estrogen sensitivity. Cancer Res. 64 (2004) 9199-9208
90. van de Vijver. Gene-expression profiling and the future of adjuvant therapy. Oncologist 10 (2005) 30-34
91. F. Yang, J.A. Foekens, J. Yu, A.M. Sieuwerts, M. Timmermans, J.G. Klijn, D. Atkins, Y. Wang, Y. Jiang, Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes pathways, Oncogene [Epub ahead of print].
92. Paik S., Kim C.Y., Song Y.K., and Kim W.S. Technology insight: application od molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat. Clin. Pract. Oncol. 2 (2005) 246-254
93. del Carmen Garcia Molina Wolgien M., da Silva I.D., Villanova F.E., Yumi Otsuka A., Borra R.C., Lima Reis L.F., et al. Differantial gene expression assessed by cDNA microarray analysis in breast cancer tissue under tamoxifen treatment. Eur J. Gyneacol. Oncol. 26 (2005) 501-504
94. Glidewell-Kenney C., Weiss J., Lee E.J., Pillai S., Ishikawa T., Ariazi E.A., et al. Mol. Cell. Endocrinol. 245 (2005) 53-59
95. McCabe A., Dolled-Filhart M., Camp R.L., and Rimm D.L. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J. Natl Cancer Inst. 97 (2005) 1808-1815
96. Choi D., Kim S., Rimm D.L., Carter D., and Haffty B.G. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J. 11 (2005) 404-411
97. Chinnaiyan P., Varambally S., Tomlins S.A., Ray S., Huang S., Chinnaiyan A.M., et al. Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int. J. Cancer (2005) (Epub ahead of prints)
98. Lin H.J., Hsieh F.C., Song H., and Lin J. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J. Cancer 93 (2005) 1372-1381
99. Rehman A., Chahal M.S., Tang X., Bruce J.E., Pommier Y., and Daoud S.S. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res. 7 (2005) R765-R774
100. Zhang D.H., Tai L.K., Wong L.L., Chiu L.L., Sethi S.K., and Koay E.S. Proteomics study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu positive breast cancer. Mol. Cell. Proteomics 4 (2005) 1686-1696
101. Schmitz K.J., Grabellus F., Callies R., Wohlschlaeger J., Otterbach F., Kimmig R., et al. Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression. Virchows Arch. (2005) 1-8 (Epub ahead of print)
102. Dobrolecki L.E., Sledge G.W., Schneider B.P., Malkas L.H., and Hickey R.J. Surface enhanced laser desorption and ionization analysis of serum from patients with metastatic breast cancer prior to undergoing taxane-based therapy, in abstracts of san antonio breast cancer symposium. Breast Cancer Res. Treat. 88 (2004) S50
103. Hu Y., Zhang S., Yu J., Liu J., and Zheng S. SELDI-TOF- MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 14 (2005) 250-255